CVR 27959350Private limited company (ApS)Forskning og eksperimentel udvikling indenfor bioteknologi (721100)Dyrehavevej 53, 2930 KlampenborgFounded 8 Oct 2004
Compare withsimilar companiesanother companyits industry
BKG-PHARMA ApS
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Cite as: BKG-PHARMA ApS, https://dandex.ai/company/27959350/bkg-pharma. Source: Dandex, from CVR, read 22 Nov 2026.
Dandex is Danish Company Data. Connect it once and ask about BKG-PHARMA ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Dandex has an MCP server at https://dandex.ai/mcp and a REST API at https://dandex.ai/api/v1.
Set up DandexEmployees
0
CVR, 2018
Gross profit
-616.4K
DKK, annual report 2016
Result
-18M
DKK, annual report 2016
Equity
-2.7M
DKK, annual report 2016
BKG HOLDING ApSCVR 28114435, 100% of capital and votes, until 27 Dec 2017
Birgit Kjældgaarduntil 27 Dec 2017
No current owner is registered.
CVR 28114435100% of capital and votesnotified 20 Sep 201731 Dec 2012 to 27 Dec 2017
BKG-PHARMA ApS holds no Danish company now.
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 3404434166.7% to under 90% of capital and votes24 Jan 2013 to 26 Dec 2017
CVR lists no current officers for this company.
Founded 8 Oct 2004.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Feb 2018, monthly: 1 employee, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Mar 2015 | Apr 2015 | May 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Jan 2018 | Feb 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 2 | 3 | 4 | 3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FTE | 1 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Feb 2018, published 3 May 2018.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2016, DKK: Gross profit -616.4K, Operating profit -18.1M, Result for the year -18M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2016, DKK: Total assets 315.6K, Equity -2.7M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2012 | 2013 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|
| Gross profit | 837 | 938 | -28 | -715 | -616 |
| Operating profit | +837 | +938 | -28 | -715 | -18,065 |
| Result for the year | +535 | +792 | -65 | -95 | -18,025 |
| Equity | 13,757 | 14,548 | 14,483 | 15,267 | -2,683 |
| Total assets | 15,146 | 15,777 | 15,623 | 18,059 | 316 |
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 1,300,000 | None | 1,300,000 | None | 1,548,836 | |
| IncreaseCashPaid in 9,999,841, cash price 208.97, implied value 51,999,259 | 208.97 | 9,999,841 | 51,999,259 | 248,836 | |
| IncreaseCashPaid in 300,032, cash price 33.40, implied value 6,712,832 | 33.40 | 300,032 | 6,712,832 | 200,983 | |
| IncreaseCashPaid in 50,001, cash price 3.34, implied value 641,299 | 3.34 | 50,001 | 641,299 | 192,000 | |
| IncreaseCashPaid in 499,965, cash price 33.40, implied value 5,912,802 | 33.40 | 499,965 | 5,912,802 | 177,030 | |
| FoundingNot read from the announcement | None | None | None | 162,061 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2012 | 2013 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|
| Gross profit growth (vækst i bruttofortjeneste) | n.m.note 1 | 12% | -103% | n.m.note 1 | n.m.note 1 |
| EBITDA | Not reportednote 2 | Not reportednote 2 | Not reportednote 2 | Not reportednote 2 | -616 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 1,673note 3 | 511note 3 | Not reportednote 4 | 1,001note 3 | 221note 3 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Merger (fusion), as the ceasing company (ophørende selskab)
Source: CVR, read 22 Nov 2026.
16 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er d. 27.12.2017 opløst ved fusion med CVR-nummer: 28114435 BKG HOLDING ApS.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 28114435 BKG HOLDING ApS (fortsættende) og CVR-nummer: 27959350 BKG-PHARMA ApS (ophørende).
Kapitalejerne i CVR-nummer: 28114435 BKG HOLDING ApS og CVR-nummer: 27959350 BKG-PHARMA ApS har i enighed besluttet, at der ikke skal udarbejdes en erklæring om kreditorernes stilling i forbindelse med fusionen. Kreditorer, hvis fordringer er stiftet forud for bekendtgørelsen om fusionen, og for hvilke der ikke er stillet særskilt sikkerhed, kan anmelde deres fordringer senest 4 uger efter denne offentliggørelse.
Ny adresse: c/o Birgit Kjældgaard Giwercman, Dyrehavevej 53B, 2930 Klampenborg
Vedtægter ændret:
31.12.2012.
Kapitalforhøjelse:
kr. 1.300.000,00 indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 1.548.836,00.
Bestyrelse:
Udtrådt af bestyrelsen:
Bo Anders Ljungqvist, den 10.04.2006.
Indtrådt i bestyrelsen:
Advokat Morten Stadil (formand), den 10.04.2006, Jeppe Viggo Christensen, den 10.04.2006.
Vedtægter ændret:
10.04.2006.
Kapitalforhøjelse:
kr. 47.853,00 indbetalt kontant, kurs 20.897,00.
Kapitalen udgør herefter kr. 248.836,00.
Vedtægter ændret:
05.10.2005.
Kapitalforhøjelse:
kr. 8.983,00 indbetalt kontant, kurs 3.340,00.
Kapitalen udgør herefter kr. 200.983,00.
Bestyrelse:
Udtrådt af bestyrelsen:
Sten Verland, den 05.10.2005.
Vedtægter ændret:
15.06.2005.
Kapitalforhøjelse:
kr. 14.970,00 indbetalt kontant, kurs 334,01.
Kapitalen udgør herefter kr. 192.000,00.
Vedtægter ændret:
30.11.2004.
Kapitalforhøjelse:
kr. 14.969,00 indbetalt kontant, kurs 3.340,00.
Kapitalen udgør herefter kr. 177.030,00.
Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af en direktør i forening to bestyrelsesmedlemmer eller af den samlede bestyrelse.
Vedtægter ændret:
08.10.2004.
Kapitalforhøjelse:
kr. 14.221,00 indbetalt kontant, kurs 3.340,00.
Kapitalen udgør herefter kr. 162.061,00.
Stiftelsesdato:
08.10.2004.
Seneste vedtægtsdato:
08.10.2004.
Kapital:
kr. 147.840,00.
Indbetalingsmåde:
kontant kr. 3.840,00 til kurs 100,00, i værdier kr. 144.000,00 til kurs 100,00.
Stiftere:
Direktør Carsten Schou, 2840 Holte, den 08.10.2004, CVR-NR. 16637734 BIOLINK CAPITAL ApS, Skovbrynet 57, 2880 Bagsværd, den 08.10.2004, CVR-NR. 28114435 BKG HOLDING ApS, Vintervej 2, 2920 Charlottenlund, den 08.10.2004.
Bestyrelse:
Bo Anders Ljungqvist, (formand), 3460 Birkerød, den 08.10.2004, Frank Knudsen, 3460 Birkerød, den 08.10.2004, Adm. direktør Sten Verland, 2880 Bagsværd, den 08.10.2004.
Direktion:
Birgit Giwercman, 2920 Charlottenlund, den 08.10.2004.
Selskabet tegnes af 12.1 Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af en direktør i for-ening med to bestyrelsesmedlemmer eller af den samlede bestyrelse.12.2 Bestyrelsen kan meddele prokura, enkel eller kollektiv.
Revision:
CVR-NR. 14119299 MUNKEBO, JENSEN & PENSBO STATSAUTORISERET REVISIONSAKTIESELSKAB, Hovedvejen 56, postboks 135, 2600 Glostrup, den 08.10.2004.
Første regnskabsår:
08.10.2004 - 31.12.2005.
Regnskabsår:
01.01 - 31.12.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 22 Nov 2026.
What Pro holds for BKG-PHARMA ApS:
Have Pro? Sign in.
P-number 1010830938Dyrehavevej 53, 2930 Klampenborg